5 enrolling by invitation. 5 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 5 | Enrolling by invitation 5 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy Step-up therapy, Standard treatment Routine treatment - Esophageal Cancer, MRD | Early Phase 1 | Enrolling by invitation | The First Affiliated Hospital with Nanjing Medical University | 65 | 2025-12-20 | 2026-01-27 |
| PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors 89Zr-LNCab104, 89Zr-LNCab103, 18F-FDG - Breast Cancer, Gastric Cancer (GC) | Early Phase 1 | Enrolling by invitation | Affiliated Hospital of Jiangnan University | 10 | 2025-07-01 | 2025-06-17 |
| The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies 18F-FDG, 89Zr-LNCab190, 89Zr-LNCab002 - Breast Cancer, Gastric Cancer (GC) | Early Phase 1 | Enrolling by invitation | Affiliated Hospital of Jiangnan University | 20 | 2025-07-01 | 2025-06-17 |
| Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Pucotenlimab Combined with Lenvatinib, Oxaliplatin plus S-1 regimen - Gastric (Stomach) Cancer | Early Phase 1 | Enrolling by invitation | Fujian Medical University | 100 | 2025-05-01 | 2026-01-21 |
| MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology - Colorectal Cancer | Early Phase 1 | Enrolling by invitation | Second Affiliated Hospital of Wenzhou Medical University | 10 | 2024-07-01 | 2026-04-28 |
Stomach Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1)
Digestive System Diseases (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Stomach Diseases (3) · Breast Diseases (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Colonic Diseases (1) · Esophageal Diseases (1)
Fluorodeoxyglucose F18 (2) · Oxaliplatin (1) · lenvatinib (1)
Affiliated Hospital of Jiangnan University (2) · Fujian Medical University (1) · Second Affiliated Hospital of Wenzhou Medical University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (5)
PMID 25691612, PMID 33538338, PMID 35708168, PMID 36990609, PMID 40115982, PMID 40914168